Companies presented very promising data for treating lung cancer at European Society of Medical Oncology (ESMO) Congress 2021.
The United States Food and Drugs Administration granted a priority review for Roche’s Tecentriq treatment for people suffering with early, non-small-cell lung cancer, the Swiss company said on Aug. 3.
In a roundup of scientific studies on the novel coronavirus, new findings shed light on why chronic lung diseases that block the airways increase patients’ risks for severe Covid-19 and researchers say the blood disorder anemia should probably be added to the list of risk factors for poorer Covid-19 outcomes.
The U.S. Food and Drug Administration granted accelerated approval of Janssen’s Rybrevant (amivantamab-vmjw) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
The U.S. Food and Drug Administration approved Genentech’s Actemra (tocilizumab) for slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease (SSc-ILD).
The gout medication colchicine will be tested in a large UK study looking into potential early-stage Covid-19 treatments and enrollment criteria was widened for the latest arm of the trial, University of Oxford researchers said on March 3.
AstraZeneca will voluntarily withdraw the use of the company’s Imfinzi to treat advanced bladder cancer in the United States after the cancer drug failed to meet post-approval requirements, the Anglo-Swedish drugmaker said.
Belgo-Dutch biotech Galapagos NV and U.S. partner Gilead Sciences Inc. will discontinue late-stage trials testing their experimental drug ziritaxestat in patients with pulmonary fibrosis.
Merck KGaA’s drug development program suffered a setback with the company’s most important experimental medicine as the cancer treatment bintrafusp alfa, being jointly developed by GlaxoSmithKline, failed early in a lead trial.
FRANKFURT (Reuters) – AstraZeneca’s top-selling drug Tagrisso has been shown to slow the spread of a certain type of lung cancer to the brain when diagnosed at an early stage, the British drugmaker said on Saturday. A study with patients diagnosed early enough for the lung tumor to be surgically removed, and who have a […]